311 related articles for article (PubMed ID: 30553166)
1. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
[TBL] [Abstract][Full Text] [Related]
2. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following Alemtuzumab treatment of Multiple Sclerosis.
Massey J; Barnett Y; Curnow J; Sutton I
Mult Scler Relat Disord; 2019 Oct; 35():100-103. PubMed ID: 31357122
[TBL] [Abstract][Full Text] [Related]
3. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
[No Abstract] [Full Text] [Related]
4. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
5. Anti-GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report.
Ratuszny D; Skripuletz T; Stüber T; Valizada E; Gehring K; Ertl P; Müller JA; Wattjes MP; Feuerhake F; Sühs KW
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37202183
[TBL] [Abstract][Full Text] [Related]
6. GABA
Maniscalco GT; Mariotto S; Höftberger R; Capra R; Servillo G; Manzo V; Napolitano M; Candelaresi P; Gerevini S; Ferrari S; Bozzetti S; Spatola M; Florio C
Neurology; 2020 Sep; 95(9):399-401. PubMed ID: 32651290
[No Abstract] [Full Text] [Related]
7. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
[No Abstract] [Full Text] [Related]
8. Immune-mediated encephalitis for the infectious disease specialist.
Venkatesan A
Curr Opin Infect Dis; 2019 Jun; 32(3):251-258. PubMed ID: 31021956
[TBL] [Abstract][Full Text] [Related]
9. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.
Wehrum T; Beume LA; Stich O; Mader I; Mäurer M; Czaplinski A; Weiller C; Rauer S
Neurology; 2018 Feb; 90(7):e601-e605. PubMed ID: 29352101
[TBL] [Abstract][Full Text] [Related]
10. A case of acute fulminant multiple sclerosis treated with alemtuzumab.
Gobbin F; Marangi A; Orlandi R; Richelli S; Turatti M; Calabrese M; Forgione A; Alessandrini F; Benedetti MD; Monaco S; Gajofatto A
Mult Scler Relat Disord; 2017 Oct; 17():9-11. PubMed ID: 29055482
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
12. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
Richter S; Wagner B; Celius EG
J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
[No Abstract] [Full Text] [Related]
13. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.
McCaughan G; Massey J; Sutton I; Curnow J
BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29212866
[TBL] [Abstract][Full Text] [Related]
14. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
15. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Metz I; Rieckmann P; Kallmann BA; Brück W
Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
[No Abstract] [Full Text] [Related]
16. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
[No Abstract] [Full Text] [Related]
17. Autoimmune encephalitis: a review of diagnosis and treatment.
Dutra LA; Abrantes F; Toso FF; Pedroso JL; Barsottini OGP; Hoftberger R
Arq Neuropsiquiatr; 2018 Jan; 76(1):41-49. PubMed ID: 29364393
[TBL] [Abstract][Full Text] [Related]
18. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
Aitken L; Patel R; D'Rozario J; Choi P
Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.
Alamo A; Condorelli RA; La Vignera S; Calogero AE
Int J Immunopathol Pharmacol; 2019; 33():2058738419843690. PubMed ID: 30968726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
